BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 33716951)

  • 1. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
    Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
    Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
    Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
    Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
    Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer.
    Yim JH; Kim EY; Bae Kim W; Kim WG; Kim TY; Ryu JS; Gong G; Hong SJ; Yoon JH; Shong YK
    Thyroid; 2013 Jan; 23(1):58-63. PubMed ID: 22973946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.
    Schlumberger M; Leboulleux S; Catargi B; Deandreis D; Zerdoud S; Bardet S; Rusu D; Godbert Y; Buffet C; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Toubert ME; Kelly A; Benhamou E; Borget I
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):618-626. PubMed ID: 29807824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
    Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
    J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer.
    Bandeira L; Padovani RDP; Ticly AL; Cury AN; Scalissi NM; Marone MMS; Ferraz C
    Arch Endocrinol Metab; 2017 Dec; 61(6):590-599. PubMed ID: 29412384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
    Barres B; Kelly A; Kwiatkowski F; Batisse-Lignier M; Fouilhoux G; Aubert B; Dutheil F; Tauveron I; Cachin F; Maqdasy S
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3462-3472. PubMed ID: 30785995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
    Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
    Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition of the Response to Initial Therapy with Radioiodine in Patients with Differentiated Thyroid Carcinoma: Basal or Stimulated Thyroglobulin?
    Rosario PW; Mourão GF; Calsolari MR
    Horm Metab Res; 2019 Oct; 51(10):634-638. PubMed ID: 31578049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
    Stevic I; Dembinski TC; Pathak KA; Leslie WD
    Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment.
    Han JM; Kim WB; Yim JH; Kim WG; Kim TY; Ryu JS; Gong G; Sung TY; Yoon JH; Hong SJ; Kim EY; Shong YK
    Thyroid; 2012 Aug; 22(8):784-90. PubMed ID: 22780573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillary Thyroid Carcinoma Recurrence: Low Yield of Neck Ultrasound With an Undetectable Serum Thyroglobulin Level.
    Epstein S; McEachern R; Khot R; Padia S; Patrie JT; Itri JN
    J Ultrasound Med; 2018 Oct; 37(10):2325-2331. PubMed ID: 29498418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer.
    Ha J; Kim MH; Jo K; Lim Y; Bae JS; Lee S; Kang MI; Cha BY; Lim DJ
    Medicine (Baltimore); 2017 Jul; 96(29):e7512. PubMed ID: 28723762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.